Arrowhead Pharmaceuticals (ARWR) is a clinical-stage company with a broad pipeline of therapies based on its TRiM RNAi platform. While Arrowhead seems some distance from having a commercial drug approval, it is working on a kind of therapy, RNAi, that other companies have successfully commercialized. It also has partnerships where it has licensed its innovative therapies to leading pharmaceutical companies. Because it already has a multibillion-dollar market capitalization, there are certainly risks that cannot be ignored, including possibly failing to get FDA or EU approval for its most advanced therapies. However, I believe